Introduction
============

Hepatocellular carcinoma (HCC) is the third most common cause of cancer death in the world and the fifth most common type of cancer. The 5-year survival rate for HCC after surgical resection remains low, with high rates of metastasis and recurrence serving as major obstacles to long-term survival after a curative resection has been performed.[@b1-ott-9-2227] The low survival rate has been attributed to a delay in diagnosis and ineffective therapeutic options.[@b2-ott-9-2227] Therefore, new diagnostic methods and therapeutic markers are needed to improve the survival of patients with this disease.

Recently, our attention has turned to the role of aberrant glycosylation in the progression and pathogenesis of various tumors. Glycosylation is an extremely important posttranslational modification of proteins. Aberrations in this process affect various physicochemical and functional properties of proteins, such as protein stability and solubility, as well as inter- and intracellular protein transport and communication.[@b3-ott-9-2227] A change in the level of expression of glycosyltransferases, including sialyltransferases, can alter oncogene-activated signaling pathways, thereby making significant changes in the glycan structures on glycoproteins.[@b4-ott-9-2227] Abnormal sialylation and changes in the expression of sialyltransferase are frequently seen in many types of cancer.[@b5-ott-9-2227] Cancer biomarkers, such as the sialyl-Lewisa epitope (CA19-9) and sialyl-Tn epitope (CA72.4), have been used as targets for the development of anticancer immunotherapy in preclinical and clinical studies of vaccines.[@b6-ott-9-2227] Sialyltransferase levels have been reported to correlate with tumorigenesis and progression in HCC. Dall'Olio et al[@b7-ott-9-2227] investigated the level of expression of the sialyltransferase ST6Gal-I and its mRNA in normal human liver tissue compared with cirrhotic tissue from patients with HCC and found that ST6Gal-I expression was the greatest in the HCC samples. This suggests that further study of sialyltransferases might provide valuable insight into the mechanisms underlying this disorder and lead to opportunities to use ST6Gal-I for identifying diagnostic, prognostic, and therapeutic approaches to HCC.

ST3Gal-I catalyzes the transfer of sialic acid in an α 2,3-linkage to terminal galactose residues on glycoproteins or glycolipids. Overexpression of ST3Gal-I may contribute to the initial oncogenic transformation in HCC and, therefore, might be useful for predicting cancer progression and recurrence. Using a breast cancer model, Picco et al[@b8-ott-9-2227] reported that when crossed with PyMT mice, ST3Gal-I transgenic mice exhibited a considerable decrease in tumor latency compared with PyMT mice on an identical background, which suggests that ST3Gal-I is a tumor promoter. Sproviero et al[@b9-ott-9-2227] found that ST3Gal-I expression is upregulated by cyclooxygenase-2 in the presence of prostaglandin E2 in the breast cancer cell line T47D. Upregulation of ST3Gal-I expression also plays an important role in the development of malignant epithelial ovarian cancer,[@b10-ott-9-2227],[@b11-ott-9-2227] colon carcinoma,[@b12-ott-9-2227] bladder cancer,[@b13-ott-9-2227] and cutaneous epithelial cancer;[@b14-ott-9-2227] however, ST3Gal-I levels did not increase significantly in gastric cancer tissue compared with adjacent normal tissue.[@b15-ott-9-2227] ST3Gal-I is strongly expressed in several types of tumors, but little is known about the mechanisms underlying its expression, regulation, or prognostic value in human HCC.

We investigated the relationship between ST3Gal-I expression in human HCC and the rate of metastasis and prognosis for the disease by analyzing its expression in HCC lines, resected HCC tissue specimens, and HCCLM3 cells in which ST3Gal-I activity had been silenced in vitro using small interfering RNA (siRNA). Specifically, we wanted to determine whether the overexpression of ST3Gal-I predicts a poor prognosis for patients with HCC.

Methods
=======

Patients and specimens
----------------------

We collected 20 random HCC tissue specimens and paired adjacent tissue samples from patients who had undergone surgical resection of HCC in the Nantong University Affiliated Hospital in Nantong City, People's Republic of China, between December 2013 and July 2014 for Western blot analysis. Tumor specimens were randomly retrieved from 273 patients with HCC in the same sample bank between January 2009 and May 2011 for use in tissue microarrays. The clinicopathological characteristics of the patients from whom these samples were taken, none of whom had received any preoperative anticancer treatment, are summarized in [Table S1](#SD1-ott-9-2227){ref-type="supplementary-material"}. The study protocol, including the use of human cell lines, was approved by the Ethics Review Board of the Nantong University Affiliated Hospital. Written informed consent was obtained from all study participants.

Follow-up and tumor recurrences
-------------------------------

Follow-up procedures are described in our previous study.[@b16-ott-9-2227] All patients whose samples were used in the tissue microarray group were observed until March 2014 over a median of 42 months (range: 0.5--61 months). The most common causes of death among these patients were recurrence, metastasis, or liver cirrhosis. Overall survival (OS) was defined as the interval between surgery and death. Disease-free survival (DFS) was defined as the interval between surgery and recurrence.

Cell culture
------------

The human HCC cell lines Hep3B and HepG2, provided as a gift from Cornell University, Ithaca, NY, USA, were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT, USA) and penicillin--streptomycin (Thermo Fisher Scientific, Waltham, MA, USA). Human HCC cell lines HCCLM3, MHCC97H, and MHCC97L, with high and low lung metastatic potential, along with normal human hepatic L02 cells, were obtained from the General Surgery Institute of our hospital. These cells were cultured in Dulbecco minimum essential medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% FBS and penicillin--streptomycin at 37°C in 5% CO~2~.

Western blot analysis
---------------------

Western blot analysis was carried out as described previously.[@b17-ott-9-2227] Briefly, cell or tissue lysates were generated and total proteins were separated using standard sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred to polyvinylidene difluoride membranes. The membranes were washed and blocked before being incubated with polyclonal antibody ST3Gal-I (R&D Systems Inc., Minneapolis, MN, USA) followed by incubation with horseradish peroxidase-conjugated secondary antibodies. The reactions were detected using an enhanced chemiluminescence assay. Glyceraldehyde-3-phosphate dehydrogenase was used as a loading control. The relative intensity of each band was determined using Image Lab 3.0 imaging methods (Bio-Rad Laboratories, Inc.; Hercules, CA, USA).

siRNA-mediated ST3Gal-I silencing
---------------------------------

Following the manufacturer's protocol, we grew HCCLM3 cells in culture in 24-well plates or 6 cm dishes to a confluence of 60%--70% and then transfected them with siRNAs targeting human ST3Gal-I (siRNA sequence: sense 5′-GAAGAGGUAUUGAAUGCUA-3′ and antisense 5′-CUUCUCCAUAACUUACGAU-3′) using the siRNA transfection reagent RNAiMAX (Invitrogen). Simultaneously, they were transfected with nontargeting control siRNA as a negative control. After 72 hours of transfection, the cells were harvested for Western blot analysis.

MTT assay, cell migration, and invasion assay
---------------------------------------------

Cells were aliquoted into a 96-well plate (5,000/100 μL per well), incubated overnight, and then exposed to ST3Gal-I siRNA for 6 hours. The medium was then replaced with 100 μL DMEM containing 10% FBS to which 10 μL of CCK-8 solution (Dojindo; Kumamoto, Japan) was added at the indicated time points. The plates were then incubated an additional 2 hours. Absorbance was measured at 450 nm to determine the number of viable cells in each well. Each experiment was carried out three times.

Cell migration was evaluated by scratch wound assay. Briefly, 10^6^ HCCLM3 cells/well were plated in a 6-well plate and cultured overnight to yield a confluent monolayer. The cells were then exposed to 10 mg/mL mitomycin for 1 hour to inhibit proliferation and then wounded with a 10 μL pipette tip. The remaining cells were washed twice and then cultured with DMEM supplemented with 2% FBS. Photographs were taken at 0, 24, and 48 hours. At the indicated times, migrating cells at the front of the wound were photographed and the percentage of the cleaned area at each time point was compared with the area at time 0. Each area was measured using Image-Pro Plus version 6.2 software.

Cell invasiveness was evaluated using a Transwell matrigel invasion assay in 24-well Transwell units (Corning, New York, NY, USA). Each well contained 10^5^ HCCLM3 cells suspended in DMEM. Seeded wells in the upper chamber were coated with matrigel and incubated with DMEM supplemented with 10% FBS; 500 μL of DMEM was applied in the lower chamber. After 24 hours, invading cells on the bottom surface were fixed with 4% paraformaldehyde and counted under a light microscope after staining with crystal violet.

Tissue microarray and immunohistochemistry
------------------------------------------

Tissue microarrays were constructed as described previously.[@b16-ott-9-2227] Immunohistochemistry was carried out as described previously.[@b16-ott-9-2227] Briefly, after neutralizing endogenous peroxidase and retrieving antigens by microwave, we preincubated the slides with blocking serum and then incubated them overnight with mouse antihuman ST3Gal-I (R&D Systems) polyclonal antibody. Sections were then incubated with a second antibody and exposed to horseradish peroxidase-conjugated streptavidin. Using a Leica CCD camera (DFC420), we captured photographs of three representative fields using Leica QWin Plus *v*3 software.

Immunohistochemical staining was assessed by two independent pathologists without the knowledge of patient characteristics. A scoring system was applied as previously described.[@b17-ott-9-2227] The staining intensity of ST3Gal-I was scored first (0: negative; 1: weak; 2: high) and then the percentage of positive cells was scored (1: 0%--25%; 2: 26%--50%; 3: 51%--75%; 4: \>75%). The final score for each sample was calculated by multiplying the staining intensity score by percentage score. Tumors with a staining index \$2 were defined as high-expression tumors.

Statistical analysis
--------------------

Statistical analysis was carried out using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Survival curves were created using the Kaplan--Meier method and compared by log-rank test. The Cox proportional hazards regression model was used for univariate and multivariate analyses, with all of the clinicopathological features used as covariates. The *χ*^2^ test, Fisher's exact probability, and Student's *t*-test were used for comparisons between groups. Statistical significance was established at *P*\<0.05.

Results
=======

ST3Gal-I expression in HCC cell lines and tissue samples
--------------------------------------------------------

ST3Gal-I expression was determined in several HCC cell lines (HCCLM3, MHCC97H, MHCC97L, HepG2, Hep3B, and L02), each with a different metastatic potential. We found that ST3Gal-I expression increased with metastatic potential: it was significantly higher in HCCLM3 and MHCC97H cells compared with MHCC97L, HepG2, and Hep3B cells (*P*\<0.05; [Figure 1A](#f1-ott-9-2227){ref-type="fig"}) and in HCC tissue (n=20) compared with paired peritumor tissue (*P*\<0.05; [Figure 1B](#f1-ott-9-2227){ref-type="fig"}).

ST3Gal-I knockdown attenuated proliferation and reduced migration and invasion of HCC cells
-------------------------------------------------------------------------------------------

To further examine the functional role of ST3Gal-I in the HCC lines, we used siRNA to silence ST3Gal-I expression in HCCLM3 cells. Successful knockdown of ST3Gal-I expression was confirmed using Western blot analysis (*P*=0.01, [Figure 2A](#f2-ott-9-2227){ref-type="fig"}). Down-regulation of ST3Gal-I resulted in a significant suppression of cell proliferation within 72 hours following transfection (*P*\<0.001; [Figure 2B](#f2-ott-9-2227){ref-type="fig"}). The Transwell matrigel invasion assay indicated that silencing of ST3Gal-I expression also significantly reduced the invasiveness of HCCLM3 cells in vitro (number of invaded cells \[controls vs siRNA\]: 137 vs 71, respectively; *P*=0.012) ([Figure 2C](#f2-ott-9-2227){ref-type="fig"}). Microscopic examinations at 24 and 48 hours following the scratch wound assay revealed a decreased migration of HCCLM3 cells in the siRNA group compared with controls (*P*\<0.001; [Figure 2D](#f2-ott-9-2227){ref-type="fig"}).

Patient clinicopathological profiles
------------------------------------

The median follow-up was 42.0 months (range: 0.5--61.0 months; standard deviation: 18 months). DFS and OS rates at 1, 3, and 5 years posthepatectomy were 79.4% and 88.7%, 56.7% and 70.1%, and 47.6% and 59.2%, respectively. At the last follow-up visit, 133 (48.72%) patients were confirmed to have had a relapse characterized by an intrahepatic recurrence (n=89), extrahepatic metastasis (n=32), or both (n=12). Additionally, 105 patients (38.46%) had died of recurrence (n=74) or a cirrhosis-related complication without recurrence (n=31).

ST3Gal-I expression and patient outcomes
----------------------------------------

Immunohistochemical staining showed that ST3Gal-I was present mainly in the tumor cell membrane, cytoplasm, or both in a focal or scattered pattern ([Figure 3A](#f3-ott-9-2227){ref-type="fig"}). Of the 273 patients with HCC, 252 (92.3%) were positive for ST3Gal-I, with 137 (50.2%) considered high-expression patients and 136 (49.8%) considered low-expression patients. Only 21 (7.7%) were negative for ST3Gal-I expression. Most of the peritumor tissue samples were negative for ST3Gal-I or demonstrated low levels of ST3Gal-I expression.

Univariate analysis indicated that compared with patients expressing low levels of ST3Gal-I, high-expression patients had a significantly worse DFS (43.93 vs 34.51 months, respectively; *P*=0.005) and OS (51.6 vs 42.06 months, respectively; *P*=0.001) ([Figure 3B](#f3-ott-9-2227){ref-type="fig"}). Multivariate analysis suggested that the level of ST3Gal-I expression was an independent predictor of OS (*P*=0.012; HR=1.662) ([Table 1](#t1-ott-9-2227){ref-type="table"}) and DFS (*P*=0.037; HR=1.464) ([Table 2](#t2-ott-9-2227){ref-type="table"}). It also revealed that liver cirrhosis (*P*=0.048, HR=1.653), tumor size (*P*\<0.001, HR=2.204), and Barcelona Clinic Liver Cancer (BCLC) stages B and C (*P*=0.005, HR=1.665) were associated with DFS ([Table 2](#t2-ott-9-2227){ref-type="table"}) and tumor size (*P*\<0.001, HR=3.574). Survival analysis revealed that BCLC stages B and C (*P*=0.012, HR=1.657) were associated with OS when integrated with ST3Gal-I expression ([Table 1](#t1-ott-9-2227){ref-type="table"}).

Because the BCLC stage represents different stages of HCC progression,[@b18-ott-9-2227] a subgroup analysis was carried out to clarify the function of ST3Gal-I expression at different stages of the disease. A univariate analysis revealed that high levels of ST3Gal-I are closely associated with accelerated recurrence during the early stages of tumor development (*P*=0.027) ([Figure 3C](#f3-ott-9-2227){ref-type="fig"}; [Table 2](#t2-ott-9-2227){ref-type="table"}) whereas multivariate analysis indicated that ST3Gal-I expression is only of borderline significance (*P*=0.051).

Correlation of ST3Gal-I expression and clinicopathological characteristics
--------------------------------------------------------------------------

To evaluate the relationship between ST3Gal-I and tumor biology, we compared clinicopathological features with ST3Gal-I expression. We found that upregulation of ST3Gal-I protein levels correlated significantly with HCC aggressiveness, for example, tumor thrombus (*P*\<0.001), tumor size (\>5 cm, *P*=0.032), and advanced tumor stage (BCLC stages B and C, *P*\<0.001; tumor node metastasis stage II--III, *P*=0.002) ([Table 3](#t3-ott-9-2227){ref-type="table"}).

Discussion
==========

In the present study, we explored the expression of ST3Gal-I in human HCC cell lines with high and low metastatic potential and resected cancer specimens. We determined that ST3Gal-I expression correlates significantly with malignant tumor behavior in HCC. Using high-throughput tissue microarrays to examine the prognostic potential of ST3Gal-I expression in tumor tissue samples surgically resected from patients with HCC, we found a significant relationship between ST3Gal-I expression and both a poor prognosis and early-stage BCLC, which suggests that upregulation of ST3Gal-I may represent an early event in tumor development.

Recently, aberrant sialyltransferase expression was found to be related to malignant behavior in many types of cancer and regarded as a poor prognostic factor.[@b11-ott-9-2227],[@b15-ott-9-2227] However, reports of the prognostic potential of sialyltransferases in patients with tumors have been few and with inconsistent results. The highest levels of ST6Gal-I expression have been seen in grade 2 HCC tumors, HCC without preexisting cirrhosis, and male patients with HCC.[@b7-ott-9-2227] Poon et al,[@b19-ott-9-2227] however, associated a decrease in tumor ST6Gal-I activity with a shorter OS in patients with HCC and found a negative correlation between tumor ST6Gal-I activity and serum levels of monosialylated alpha-fetoprotein. By contrast, Patani et al[@b20-ott-9-2227] associated high levels of ST6GalNAc-I expression in breast cancer tissue with a better prognosis.

Increasing amounts of evidence have demonstrated that ST3Gal-I plays an important role in key pathophysiological events during various stages of tumor progression, including invasion and metastasis. Wang et al[@b11-ott-9-2227] suggested that altered expression of sialyltransferase ST3Gal-I mRNA is important in malignant ovarian cancer. ST3Gal-I expression was significantly increased in colorectal cancer specimens compared with specimens of normal mucosal tissue and specimens obtained in the presence of local lymph invasion.[@b21-ott-9-2227] Our results were consistent with these reports. Furthermore, we demonstrated that silencing of ST3Gal-I expression significantly reduces the invasive and migratory characteristics of HCCLM3 cells in vitro. Nevertheless, Zhang et al[@b22-ott-9-2227] reported that ST3Gal-I is down-regulated in the HCC cell lines HepG2 and SMMC-7721 compared with the normal hepatic cell line L02. It has also been reported that there is no significant difference in ST3Gal-I transcription levels in MHCC97H versus MHCC97L cells.[@b23-ott-9-2227] Conflicting information has also been reported concerning the role of ST3Gal-I expression in breast cancer. Down-regulation of ST3Gal-I has been associated with breast cancer,[@b24-ott-9-2227] but Picco et al[@b8-ott-9-2227] found that overexpression of ST3Gal-I promotes mammary tumorigenesis. These findings suggest that further study is needed to determine the role of different patterns of ST3Gal-I expression in different types of tumors. We also found that upregulation of ST3Gal-I significantly correlates with HCC aggression, including tumor thrombus, large tumor size, and advanced tumor stage. These results strongly indicate that ST3Gal-I is involved in HCC cell migration or metastasis and is related to a poor prognosis for patients with HCC.

It is now well established that malignant tumor behavior may result from the upregulation of sialyltransferase activity during tumor biosynthesis; unfortunately, the precise molecular mechanisms underlying this process remain unknown. Solatycka et al[@b24-ott-9-2227] demonstrated that changes in the structure of O-linked oligosaccharides that result in the appearance of T antigens are at least partially associated with the upregulation of mucin1, which down-regulates the expression of ST3Gal-I in T47D cells. It is well known that the tumor microenvironment and inflammation play vital roles in liver cancer. It was suggested that the increased sialylation on the liver membrane of Engelbreth-Holm-Swarm-bearing mice is associated with upregulation of sialyltransferase expression, which plays a role in tumor-induced liver inflammation, and that ST3Gal-I is upregulated in the liver of tumor-bearing mice compared with non-tumor-bearing controls.[@b25-ott-9-2227] Recently, it was reported that ST6Gal-I can regulate the invasiveness and chemosensitivity of HCC tumors by regulating the activity of the PI3K/Akt pathway in MHCC97H and MHCC97L cells.[@b23-ott-9-2227] These findings suggest that ST3Gal-I can serve as a target for the development of molecular therapeutic agents against HCC.

Thus far, sialyltransferase inhibitors have been used to study the role of sialylation in cancer progression and metastasis. They may serve as potent antimetastatic agents in future therapeutic applications. The sialyltransferase inhibitor KI-8110 efficiently down-regulated the pulmonary metastatic potential of murine NL-17 colon adenocarcinoma cells[@b26-ott-9-2227] by inhibiting the platelet-derived growth factor-dependent growth of cancer cells.[@b27-ott-9-2227] Soyasaponin I, the first CMP-Neu5Ac competitive inhibitor of ST3Gal-I in vivo,[@b28-ott-9-2227] enhanced cell adhesion and decreased the migratory and pulmonary metastatic potential of B16F10 melanoma cells in mice.[@b29-ott-9-2227] Additionally, AL10 inhibited the adhesion, migration, and invasiveness of human lung cancer cells overexpressing ST3Gal-I, A549, and CL1.5. It was also associated with reduced integrin signaling and significant suppression of experimentally-induced lung metastasis.[@b30-ott-9-2227] The findings of our study and the research described thus far suggest that sialyltransferase inhibitors can reduce the invasive behavior of tumor cells and, thus, might serve as a target for developing new treatment strategies for patients with HCC.

In conclusion, the present study has associated ST3Gal-I expression with a worse prognosis and increased tumor invasiveness in HCC. We propose, therefore, that ST3Gal-I may be an appropriate target for developing molecular therapeutic approaches to HCC.

Supplementary material
======================

###### 

Clinicopathologic characteristics of the HCC patients

  Indexes                 Characteristics   Number   \%
  ----------------------- ----------------- -------- ------
  Age (years)             ≤50               133      48.7
                          \>50              140      51.3
  Sex                     Female            43       15.8
                          Male              230      84.2
  Liver cirrhosis         No                240      87.9
                          Yes               33       12.1
  HBsAg                   Negative          46       16.8
                          Positive          227      83.2
  HCV                     Negative          269      98.5
                          Positive          4        1.5
  γ-GT (U/L)              ≤54               123      45.1
                          \>54              150      54.9
  AFP (ng/mL)             ≤20               171      62.6
                          \>20              102      37.4
  Child--Pugh score       A                 254      93.0
                          B                 19       7.0
  Tumor differentiation   I--II             205      75.1
                          III--IV           68       24.9
  Tumor size (cm)         ≤5                182      66.7
                          \>5               91       33.3
  Tumor number            Single            236      86.4
                          Multiple          37       13.6
  Tumor encapsulation     Complete          138      50.5
                          None              135      49.5
  Tumor thrombus          No                199      72.9
                          Yes               74       27.1
  TNM stage               I                 123      45.1
                          II--III           150      54.9
  BCLC stage              A                 185      67.8
                          B and C           88       32.2

**Abbreviations:** HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; γ-GT, γ-glutamyl transferase; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; TNM stage, tumor node metastasis stage; BCLC, Barcelona Clinic Liver Cancer.

This study was funded by the National Natural Science Foundation of China (Grant 81401988), the Special Project for Clinical Medicine of Jiangsu Province Department of Science and Technology (Grant BI2014060), and the Project of Nantong Science and Technology Bureau, Jiangsu Province, China (Grant MS22015116). No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.
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![Expression of ST3Gal-I in HCC cell lines and HCC tissue samples.\
**Notes:** Using Western blot analysis, we detected ST3Gal-I expression in hepatic and HCC cell lines (**A**); expression of ST3Gal-I was increased in 20 tumor tissues compared with peritumor tissues (**B**), ^\*^*P*\<0.05.\
**Abbreviations:** HCC, hepatocellular carcinoma; GADPH, glyceraldehyde 3-phosphate dehydrogenase.](ott-9-2227Fig1){#f1-ott-9-2227}

![Function analysis after ST3Gal-I siRNA in HCCLM3.\
**Notes:** siRNA efficiently down-regulated the expression of ST3Gal-I protein in HCCLM3 cells (**A**). Cell proliferation was detected by MTT assay. Mean + SD was calculated for data derived from individual experiments with three replicate assays (**B**). After knockdown of ST3Gal-I expression, cellular invasion (**C**) and migration (**D**) of HCCLM3 was reduced compared with controls. Magnification: ×200 (**C**) and ×100 (**D**). ^\*^*P*\<0.005.\
**Abbreviations:** siRNA, small interfering RNA; SD, standard deviation; GADPH, glyceraldehyde 3-phosphate dehydrogenase; h, hours; d, day; OD, optical density; MTT, 3-(4, 5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide.](ott-9-2227Fig2){#f2-ott-9-2227}

![ST3Gal-I expression in tissue microarrays and Kaplan--Meier curves of survival differences between HCC patients.\
**Notes:** Representative images of ST3Gal-I in HCC tumor tissues microarrays (**A**), magnification: ×40, ×200, respectively. Kaplan--Meier analysis of DFS and OS for ST3Gal-I expression in 273 cases (**B**) and Kaplan--Meier analysis of DFS of ST3Gal-I in early stage cases (**C**).\
**Abbreviations:** HCC, hepatocellular carcinoma; OS, overall survival; DFS, disease-free survival; BCLC, Barcelona Clinic Liver Cancer.](ott-9-2227Fig3){#f3-ott-9-2227}

###### 

Univariate and multivariate analyses of prognostic factors associated with survival

  Variables                                  OS                          
  ------------------------------------------ --------- --------- ------- --------------
  AFP level, ng/mL (≤20 vs \>20)             0.018     NS                
  γ-GT, U/L (≤54 vs \>54)                    0.002     NS                
  HBV                                        0.212     NA                
  Liver cirrhosis (no vs yes)                0.687     NA                
  Tumor differentiation (I--II vs III--IV)   0.05      NS                
  Tumor size, cm (≤5 vs \>5)                 \<0.001   \<0.001   3.574   2.241--5.286
  Tumor number (single vs multiple)          0.552     NA                
  Encapsulation (complete vs none)           0.214     NA                
  Tumor thrombus (no vs yes)                 0.001     NS                
  TNM stage (I vs II--III)                   \<0.001   NS                
  BCLC stage (A vs B and C)                  0.001     0.012     1.657   1.121--2.439
  ST3Gal-I (low vs high)                     0.001     0.012     1.662   1.123--2.477

**Notes:** Univariate analysis was calculated by the Kaplan--Meier method (the log-rank test). Multivariate analysis was done using the Cox multivariate proportional hazards regression model with stepwise manner (forward, likelihood ratio).

**Abbreviations:** AFP, alpha-fetoprotein; γ-GT, γ-glutamyl transferase; TNM stage, tumor node metastasis stage; BCLC stage, Barcelona Clinic Liver Cancer stage; OS, overall survival; HR, hazard ratio; CI, confidence interval; NS, not significant; NA, not applicable; HBV, Hepatitis B Virus.

###### 

Univariate and multivariate analyses of ST3Gal-I associated with early and late recurrence

  Variables                                   DFS                         
  ------------------------------------------- --------- --------- ------- --------------
  Early stage                                                             
   AFP level, ng/mL (≤20 vs \>20)             0.203     NA                
   Tumor size, cm (≤5 vs \>5)                 \<0.001   \<0.001   2.452   1.569--3.833
   Tumor number (single vs multiple)          0.476     NA                
   Encapsulation (complete vs none)           0.715     NA                
   Tumor differentiation (I--II vs III--IV)   0.612     NA                
   ST3Gal-1 (low vs high)                     0.027     0.051             
  Tissue microarray (TMA) assay                                           
   AFP level, ng/mL (≤20 vs \>20)             0.034     NS                
   γ-GT, U/L (≤54 vs \>54)                    0.002     NS                
   HBV                                        0.352     NA                
   Liver cirrhosis (no vs yes)                0.041     0.048     1.653   1.021--2.664
   Tumor differentiation (I--II vs III--IV)   0.266     NA                
   Tumor size, cm (≤5 vs \>5)                 \<0.001   \<0.001   2.204   1.564--3.127
   Tumor number (single vs multiple)          0.357     NA                
   Encapsulation (complete vs none)           0.165     NA                
   Tumor thrombus (no vs yes)                 0.001     NS                
   TNM stage (I vs II--III)                   \<0.001   NS                
   BCLC stage (A vs B--C)                     0.001     0.005     1.665   1.171--2.357
   ST3Gal-I (low vs high)                     0.007     0.037     1.464   1.021--2.093

**Notes:** Univariate analysis was calculated by the Kaplan--Meier method (the log-rank test). Multivariate analysis was done using the Cox multivariate proportional hazards regression model with stepwise manner (forward, likelihood ratio).

**Abbreviations:** AFP, alpha-fetoprotein; γ-GT, γ-glutamyl transferase; TNM stage, tumor node metastasis stage; BCLC stage, Barcelona Clinic Liver Cancer stage; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; NS, not significant; NA, not applicable; HBV, Hepatitis B Virus.

###### 

Correlation of clinicopathologic characteristics with ST3Gal-I expression

  Characteristics         ST3Gal-I (n=273)                        
  ----------------------- ------------------ ----- ----- -------- ---------
  Age (years)                                            2.667    0.102
   ≤50                    133                73    60             
   \>50                   140                63    77             
  Sex                                                    0.469    0.493
   Female                 44                 24    20             
   Male                   229                112   117            
  HBsAg                                                  0.225    0.894
   No                     46                 26    20             
   Yes                    227                113   114            
  AFP (ng/mL)                                            1.45     0.228
   ≤20                    102                46    56             
   \>20                   171                90    81             
  γ-GT (U/L)                                             1.322    0.25
   ≤54                    123                66    57             
   \>54                   150                70    80             
  Tumor differentiation                                  0.001    0.972
   I--II                  205                102   103            
   III--IV                68                 34    34             
  Tumor size (cm)                                        4.579    0.032
   ≤5                     182                99    83             
   \>5                    91                 37    54             
  Tumor number                                           0.023    0.879
   Single                 236                118   118            
   Multiple               37                 18    19             
  Encapsulation                                          0.092    0.762
   None                   138                70    68             
   Complete               135                66    69             
  Tumor thrombus                                         12.272   \<0.001
   No                     199                112   87             
   Yes                    74                 24    50             
  TNM stage                                              9.584    0.002
   I                      123                74    49             
   II--III                150                62    88             
  BCLC stage                                             12.846   \<0.001
   A                      185                106   79             
   B and C                88                 30    58             

**Note:** Statistical analyses were done by the *χ*^2^ test.

**Abbreviations:** AFP, alpha-fetoprotein; HBsAg, hepatitis B surface antigen; γ-GT, γ-glutamyl transferase; TNM stage, tumor node metastasis stage; BCLC stage, Barcelona Clinic Liver Cancer stage.
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